Lilly Walks Away As Roche Dominates EU’s COVID-19 Antibody Market

Sales Dwindled After Delta Fears

Still going strong in the US, Lilly has lost out to Roche’s Ronapreve in the European Union.  

Eli Lilly logo sign atop Lilly Biotechnology Center
Lilly's revenues have exceed expectations this year thanks to US sales of its COVID-19 antibody therapy - but the picture is very different in Europe. • Source: Alamy

More from Business

More from Scrip